be influenced by both the product transfer process and the receipt
of manufacturing site transfer approvals from appropriate regulatory
- We do expect revenue growth associated with product transfer
activities for 2008 but, while such activities will generate
positive margins, the margin percentage is expected to be dilutive
to overall margins as we hire and train new personnel in
anticipation of the commercial phase of the contract.
- Several potential new business opportunities have been identified as
a result of increased marketing and outreach activities initiated
during 2007. However the rate of conversion of such opportunities to
new business contracts over the next several quarters has introduced
increased forecasting variability.
- The timing and extent of radiopharmaceutical product introductions
to European markets is highly dependent on receiving timely
regulatory approvals, although additional approvals are expected
during 2008, in several different countries. The Company is actively
working to establish one or more appropriate marketing and
distribution partnerships, which will influence the rate at which
product sales will grow in the EU markets.
- Revenue and earnings from the potential introduction of DRAXIMAGE(R)
Sestamibi will depend on several factors including regulatory
approvals, competitive activity, manufacturing execution, marketing
and distribution partnerships and market acceptance following
product launch. This is expected to be a significant product for the
Company and the variability around its introduction alone is
expected to impact the accuracy of future forecasts for 2008
|SOURCE DRAXIS Health Inc.|
Copyright©2008 PR Newswire.
All rights reserved